The estimated Net Worth of Lisa La Vange is at least $466 Tisíc dollars as of 3 September 2024. Lisa Vange owns over 650 units of Simulations Plus stock worth over $223,370 and over the last 5 years he sold SLP stock worth over $160,027. In addition, he makes $82,263 as Independent Director at Simulations Plus.
Sign up
Lisa LaVange SLP stock SEC Form 4 insiders trading
Lisa has made over 5 trades of the Simulations Plus stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 650 units of SLP stock worth $23,368 on 3 September 2024.
The largest trade he's ever made was selling 992 units of Simulations Plus stock on 27 July 2023 worth over $48,896. On average, Lisa trades about 119 units every 14 days since 2019. As of 3 September 2024 he still owns at least 6,808 units of Simulations Plus stock.
You can see the complete history of Lisa Vange stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lisa LaVange biography
Dr. Lisa LaVange Ph.D. serves as Independent Director of the Company. Dr. LaVange currently serves as Professor and Associate Chair of the Department of Biostatistics in the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill. At UNC, she directs the establishment of a new Master's in Public Health (MPH) program with a concentration in data science, and is planning a regulatory science curriculum focused on statistical methodologies in two areas: precision medicine and real-world evidence. In addition, she is currently Principal Investigator (PI) of the coordinating centers for two large and complex trial networks: the NICHD-sponsored Adolescent Medicine Trials in HIV/AIDS Interventions Network (ATN) and the NHLBI-sponsored Precision Medicine in Severe and Exacerbation-Prone Asthma Network (PreciSE). From 2011 to 2017, Dr. LaVange served as Director of the Office of Biostatistics in the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA). In this role, she directed 215 statistical reviewers, analysts, and support staff involved in the development and application of statistical methodology for drug regulation. She was responsible for statistical review of all investigational drugs, therapeutic biologics, biosimilar products, and generic drugs. She also chaired the Statistical Policy Council and was a member of CDER's Medical Policy Council, setting statistical policy and overseeing statistical guidance development and publication for the Center. Previously, she worked for six years at Quintiles, Inc. (now IQVIA), serving as Vice President of Biostatistics for her last three years. Quintiles is the largest pharmaceutical outsourcing services company in the U.S. In this role, she directed over 200 statisticians and programmers located in five offices across North America, supporting clinical trial operations, regulatory submissions, and post-marketing evaluations for a variety of large and small pharmaceutical and biotechnology compani
What is the salary of Lisa LaVange?
As the Independent Director of Simulations Plus, the total compensation of Lisa LaVange at Simulations Plus is $82,263. There are 15 executives at Simulations Plus getting paid more, with Shawn M. O'Connor having the highest compensation of $544,231.
How old is Lisa LaVange?
Lisa LaVange is 66, he's been the Independent Director of Simulations Plus since 2019. There are 4 older and 10 younger executives at Simulations Plus. The oldest executive at Simulations Plus Inc. is Walter S. Woltosz M.A.S., M.S., 76, who is the Co-Founder & Chairman.
What's Lisa LaVange's mailing address?
Lisa's mailing address filed with the SEC is 42505 10TH STREET, WEST, , LANCASTER, CA, 93534.
Insiders trading at Simulations Plus
Over the last 21 years, insiders at Simulations Plus have traded over $70,055,940 worth of Simulations Plus stock and bought 24,000 units worth $1,395,840 . The most active insiders traders include Walter Swoltosz Virginia E ..., Walter S Woltosz a Momoko A Beran. On average, Simulations Plus executives and independent directors trade stock every 37 days with the average trade being worth of $571,025. The most recent stock trade was executed by Jill Fiedler Kelly on 9 September 2024, trading 2,250 units of SLP stock currently worth $21,848.
What does Simulations Plus do?
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
What does Simulations Plus's logo look like?
Complete history of Lisa Vange stock trades at Simulations Plus
Simulations Plus executives and stock owners
Simulations Plus executives and other stock owners filed with the SEC include:
-
Shawn M. O'Connor,
Chief Exec. Officer -
Shawn O'Connor,
Chief Executive Officer -
William Frederick,
CFO & Sec. -
John DiBella,
President, Lancaster Division -
John Anthony DiBella M.S.,
Pres of Lancaster Division -
Thaddeus Grasela,
Senior Advisory Capacity -
John Kneisel,
Chief Financial Officer -
Jill Fiedler-Kelly M.S., MS,
Pres of Cognigen Division -
Dr. Brett A. Howell Ph.D.,
Pres of DILIsym Services, Inc -
Dr. Brett A. Howell,
Pres of DILIsym Services, Inc -
John Paglia,
Independent Director -
Daniel Weiner,
Independent Director -
David Ralph,
Independent Director -
Walter Woltosz,
Chairman of the Board -
Walter S. Woltosz M.A.S., M.S.,
Co-Founder & Chairman -
Lisa LaVange,
Independent Director -
Renee Bouche,
IR Contact Officer -
Jill Fiedler-Kelly,
President - Cognigen division -
Dr. Scott Q. Siler,
Chief Scientific Officer of DILIsym Services, Inc -
Lindsay Luke,
Exec. Director of HR -
Arlene Padron,
Corp. Director of Marketing -
Viera Lukacova Ph.D.,
Chief Scientific Officer -
Argenio David Z D,
Director -
Brett Howell,
Business Unit President -
Steven Chang,
President, Immunetrics -
William W Frederick,
CFO -
Walter Swoltosz Virginia E ...,
-
Walter S Woltosz,
Director -
Richard R Weiss,
Director -
Momoko A Beran,
Chief Financial Officer -
Harold Wayne Rosenberger,
Director -
Jeffrey A Dahlen,
VP, Research & Development -
Virginia E Woltosz,
Secretary/Treasurer -
Ronald F Creeley,
VP Marketing & Sales -
Daniel Szot,
Chief Revenue Officer -
Sharlene Evans,
Director